ABSTRACT
INTRODUCTION
Cervical cancer is the third most common cancer in women worldwide, with approximately 530,000 new cases and 275,000 deaths in 2008. 1 In year 2010 in Hong Kong, there were 400 new cases (ranked 10th in incidence of all new cancer cases) and 146 deaths (ranked 9th in cancer mortality) from cervical cancer. 2 Early stage of the disease can be treated with radical surgery or radiotherapy, with 5-year survival of 75% to 80% with both treatment modalities. 3 Data from randomised trials and a systematic review show that radical cisplatin-based chemoirradiation improves survival in patients with locally advanced disease and is, therefore, considered the standard of care. In addition, concomitant chemotherapy and radiotherapy is effective in preventing local and distant recurrence versus radiotherapy alone. 4 Lymph node metastasis is a strong poor prognostic factor for cervical cancer leading to 30% to 40% reduction in 5-year survival. 5 Pelvic radiotherapy has been shown to control most of the pelvic disease and is associated with a 16% to 17% rate of residual disease. 6, 7 Extended-field radiotherapy for metastatic para-aortic lymph nodes can also achieve a 5-year survival rate of 30% to 35%. 8, 9 However, heterogeneity exists among different trials including extent of surgery and lymph node dissection, radiation dose, chemotherapy agents, and intensity. The optimal sequence and extent of treatment required in these groups of patients remain unclear.
In this study, we aimed at evaluating the outcomes of cervical cancer patients with or without pelvic and / or para-aortic lymph node involvement after radical treatment. Overall survival, cancer-specific survival, relapse-free survival, failure pattern, and complication rates were evaluated.
METHODS

Patient Selection
Patients with biopsy-proven cervical cancer referred for radical radiotherapy or chemoirradiation were included. International Federation of Gynecology and Obstetrics (FIGO) 2008 was used for staging. Routine workup included pelvic examination under anaesthesia, cystoscopy, ultrasonography of both kidneys, and chest X-ray. Sigmoidoscopy was done in selected patients with suspicious rectal involvement. Diagnostic imaging including computed tomography (CT), magnetic resonance imaging (MRI), or positron-emission tomography was not performed routinely. Patients were allowed to enter the study after surgical staging and lymphadenectomy.
Radiotherapy
All patients had CT simulation for radiation planning. The CT films were reviewed by clinical oncology specialists. Any lymph node with short axis diameter of ≥1 cm on axial slices or with necrotic centre was considered pathological. Radiotherapy consisted of external radiotherapy (ERT) and brachytherapy. ERT was delivered by 6 or 15 megavolt photon from linear accelerator using four field-box techniques (anteriorposterior and lateral-opposing fields). The clinical target volume for radiotherapy included the cervix, uterus, and regional lymph nodes (internal iliac, obturator, upper pre-sacral). Anterior-posterior field extended from L4/5 junction to the inferior aspect of ischial tuberosity (or at least 3 cm below the gross tumour in the vagina) and 1.5 cm beyond the pelvic brim laterally. Lateral field borders were at anterior 2/3 of the pubic symphysis and 0.5 cm beyond the S1/2 junction. Dose of 50 Gy in 2 Gy daily fraction was given (4-cm width median shield added after 40 Gy). Additional external beam parametrial boost of 6 or 8 Gy was given if there was involvement of the parametrium or pelvic side wall, respectively. Lymph nodes were boosted to a total of 60 to 64 Gy radiotherapy. Para-aortic nodal metastases were treated upfront by extended-field ERT, covering both the para-aortic region and whole pelvis with a dose of 30 Gy in 2 Gy per fraction, followed by split-field 3-dimensional conformal boosted radiation of 20 Gy. Para-aortic field extended from T12/L1 to L4/5 junction and was matched with upper border of pelvic field. Lateral border was 4 cm from the midline (with at least 1.5 cm margin from involved lymph nodes). Routine intracavitary brachytherapy, parametrial boost, and
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Intracavitary brachytherapy using Rotterdam applicator was administered twice weekly. Dose of 6.5 Gy per application for four or 7.7 Gy per application for three at Manchester point A was delivered by high-dose-rate after-loading technique (Iridium-192 source).
Chemotherapy
Patients aged ≤70 years and with adequate organ function (total white cell count ≥3.0 x 10 9 /L, absolute neutrophil count ≥1.5 x 10 9 /L, platelet count ≥100 x 10 9 /L, normal liver function test, creatinine clearance Cockroft-Gault formula ≥40 ml/min) received weekly cisplatin 40 mg/m 2 concurrent with radiotherapy. A maximum of 6 cycles were permitted.
Follow-up Plan
Patients were first assessed 8 weeks after completion of treatment. Subsequent follow-up was scheduled every 3 months in the first 2 years, every 6 months from third to fifth year, and then yearly thereafter. Pelvic and cervical smear examinations were done at every follow-up visit. Diagnostic imaging was used only when there was suspicion of residual disease or distant metastases.
Statistical Analysis
Differences in patient demographics and disease characteristics between the groups with and without lymph node metastases were examined by Chi-square or Fisher's exact test. Overall survival was defined as the time from histological diagnosis of cervical cancer to date of death from any causes. Cancer-specific survival was similar to overall survival but with data censored at the occurrence of non-cancer death. Relapse-free survival included any relapses related to cervical cancer in addition to death. Survival curves were generated by the Kaplan-Meier method and any differences between survival curves were examined by 2-sided log-rank test. The Cox proportional hazard regression model was used to evaluate the prognostic factors including age, histology, FIGO stage, presence of lymph node metastases, concurrent use of chemotherapy, and overall treatment time (calculated from the date of commencement to date of completion of radiotherapy including both ERT and brachytherapy). Overall treatment time was stratified by ≤56 days versus >56 days during analysis, based on recommendations from the Royal College of Radiologists 10 and data from various trials. 11, 12 Radiation Therapy Oncology Group (RTOG) acute and late radiation morbidity scoring criteria were used to evaluate toxicities. 13 
RESULTS
Patient Demographics and Disease Characteristics
The study included a total of 137 consecutive patients with histologically proven cervical cancer treated with radical radiotherapy or chemoirradiation from May 2007 to December 2012. Of them, 37 had pelvic and / or para-aortic lymph node involvement (group A). Only three (8%) patients had pathological diagnosis of lymph node involvement during initial surgical attempts for their FIGO stage Ib1 disease. The remaining 34 (92%) patients were diagnosed with lymph node involvement based on radiotherapy-planning CT scan findings. Patients in group A were younger than those in group B (median age, 49 years vs. 59 years; p < 0.001). The majority of patients (91%, n = 125) had squamous cell carcinoma. Other histologies included adenocarcinoma (n = 8), adenosquamous cell carcinoma (n = 2), and poorly differentiated carcinoma (n = 2). The distributions of FIGO stage were similar among the two groups with approximately 80% patients having FIGO stage IIb-IIIb diseases (Table 1) .
Treatment Received
Overall, 72% (n = 99) of patients received concurrent chemotherapy with radiotherapy. Median number of chemotherapy cycles administered was 6.5 (range, 1-7) in group A and 5 (range, 2-7) in group B (Table 1) . Five patients (n = 1 in group A, 3%; n = 4 in group B, 4%) had temporary suspension of radiation due to personal affairs (n = 3) and medical conditions (cardiovascular event and obstructive nephropathy requiring interventions; n = 2). Overall treatment time was more than 56 days in two patients (both from group B; Table  1 ).
Survival Outcomes
After a median follow-up of 31 (range, 2-72) months, 11 (30%) patients in group A and 21 (21%) patients in group B died. The 3-year overall survival rate in group A (60%) was lower than that in group B (75%) but it did not reach statistical significance (hazard ratio [HR] = 1.90; 95% confidence interval [CI], 0.91-3.97; p = 0.08; Figure a) . The 5-year overall survival rate was 51% and 63% in groups A and B, respectively. Among the four patients with para-aortic lymph node metastases, two died from the disease and two survived without disease. Of the two patients who survived, one had low paraaortic lymph node involvement at L5 (at a follow-up of 30 months) and the other had undergone excision of the lower para-aortic nodes during the initial attempt for radical surgery for FIGO stage IB disease (at a followup of 66 months, Table 2 ).
Non-cancer deaths were observed in two patients from group A (chest infection, n = 1; slipped and fell, n = 1) and six patients from group B (chest infections, n = 2; suicide, n = 1; road traffic accident, n = 1; massive cerebral infarct, n = 1; acute leukaemia, n = 1). After excluding these non-cancer deaths, the 3-year cancerspecific survival remained lower in group A (64%) than in group B (81%; HR = 2. Multivariate analysis showed that lymph node metastasis, advanced FIGO stage III-IVa, poorly differentiated histology, and overall treatment time of >56 days were significant poor prognostic factors for overall survival (Table 3) . The same factors, except poorly differentiated histology, determined poor relapsefree survival (Table 4) .
Lymph node characteristics such as number, laterality, size, and site of lymph node involvement were not significant in multivariate analysis for survival in group A patients.
Pattern of Failure
Pelvic relapses occurred in four (11%) patients from group A and five (5%) patients from group B, giving rise to pelvic disease control rate of 89% and 95%, respectively. Distant metastases were the most common sites of initial failure in both groups (77% in group A and 84% in group B), occurring after a median time of 9.6 (range, 1.3-39.6) months. Sub-sites of distant metastases and respective frequencies of involvement are shown in Table 5 .
Adverse Events
Acute grade 1-2 toxicities were common ( Figure. Kaplan-Meier analysis of (a) overall survival, (b) cancerspecific survival, and (c) relapse-free survival in group A (with lymph node metastases) and group B (no lymph node metastases). P values were calculated by log-rank test stratified according to lymph node status. Abbreviations: CI = confidence interval; HR = hazard ratio; LN = lymph node.
(a) (c) (b)
grade 3-4 haematological toxicities occurred in around 25% of patients (7% anaemia, 18% neutropenia, 2% thrombocytopenia).
Chronic grade 3-4 gastrointestinal or genitourinary toxicities were observed in 4% (6/137) of patients (Table  6 ). Three patients developed enterovaginal fistula (biological effective doses [BEDs] using α/β ratio of 3 = 105 Gy 3 , 144 Gy 3 , and 131 Gy 3 in the three patients) and two patients developed proctitis requiring surgery (BEDs = 114 Gy 3 and 103 Gy 3 in the two patients). One patient had cystitis with frequent haematuria (BED = 117 Gy 3 ) and this patient had posterior bladder wall invasion on presentation. All four patients received extended-field chemoirradiation and had no grade 3-4 acute or chronic toxicities.
DISCUSSION
Lymph node metastases in cervical cancer were not uncommon and the risk varied with FIGO stage. Incidence of pelvic and para-aortic lymph node metastases was 12% to 22% and 2% to 4% in stage I or 15% to 46% and 7% to 20% in stage II-III disease, respectively. 6 Outcomes of these patients remained poor despite advancement in treatment.
The 5-year survival of our patients with lymph node metastases after definitive treatment was 51%, which was similar to that from previously published data of 50% to 80%, depending on the disease stage. 14 In those studies, extended-field radiotherapy for metastatic paraaortic lymph nodes resulted in a 5-year survival of 30% to 35%. 9, 15 There has been much concern about the toxicity associated with extended-field radiotherapy when given with concurrent chemotherapy as the RTOG 92-10 trial found that such approach was highly toxic, with cumulative late grade 3-4 toxicity of 34% at 3 years. 16 Among our four patients treated with extendedfield chemoirradiation, two survived until the end of this study although both had relatively small volume of disease. No acute or chronic grade 3-4 toxicities were recorded. However, these observations should be interpreted carefully due to the small number of patients, variations in pretreatment staging (one patient had surgical staging) and chemotherapy given (2 patients received only 1 cycle of concurrent weekly cisplatin due to subjective intolerance, and one received additional 6 cycles of chemotherapy before radical treatment). As opposed to other studies, 17, 18 lymph node characteristics such as number, laterality, size, and site of lymph node involvement were not significant prognostic factors for survival in our patients with lymph node involvement, but this may be due to the small sample size of 37 patients.
Radiotherapy has been shown to be effective in treating cervical cancer. A retrospective study in 1211 cervical cancer patients after radiotherapy alone found pelvic failure rate of 9.6% to 40% in stage Ib-III disease. 12 Rate of residual pelvic and para-aortic lymph Table 5 . Pattern of failure in group A and group B.
* p = 0.047. Table 6 . Toxicities according to Radiation Therapy Oncology Group criteria.
Adverse event No. (%)
Group A (with lymph node metastases, n = 37)
Group B (without lymph node metastases, n = 100) Overal (n = 137) nodes after radiotherapy was around 16% and 12%, respectively. 7 Comparable pelvic disease control rates of 89% (with lymph node metastases) and 95% (without lymph node metastases) were observed in our study. Despite such high pelvic disease control after radical radiotherapy with or without chemotherapy, incidence of distant metastasis remains a major challenge and it ranges from 30% to 45%. 19, 20 Our patients were no exception, and significantly more relapses occurred in patients with lymph node metastases versus those without lymph node metastases (35% vs. 19%, p = 0.047). Among those patients with relapse, distant metastases were the most common sites of first relapse occurring at a median time of 9.6 months (range, 1.3-39.6 months). The short period from completion of radiotherapy to distant recurrence and absence of concurrent pelvic relapse indicates that metastases might have developed early, before the completion of treatment.
Two potential ways have been explored to help decrease distant failure. The first is by improving pelvic control. A retrospective multivariate analysis of 1211 cervical cancer patients demonstrated a 40% to 60% increased risk of distant dissemination with failure of pelvic control. 21 Incorporation of lymphadenectomy and escalation of radiation dose have been proposed to improve pelvic control.
The rationale behind undertaking lymphadenectomy was to remove bulky lymph nodes which are potentially radioresistant and persist after radiotherapy, leading to metastatic disease. A theoretical model suggests a survival advantage from surgical debulking of enlarged pelvic lymph nodes but the benefit was small, in terms of 1%, 2%, and 4% in stage IB, IIB, and IIIb disease, respectively.
14 However, these estimates were based on assumptions that were not universally accepted. A retrospective review (193 cervical cancer patients) performed in the Prince of Wales Hospital, Hong Kong, also showed that debulking enlarged pelvic nodes helped to reduce pelvic recurrence but did not improve survival due to high extra-pelvic recurrences (59.1% in early and 44.8% in advanced stage). 22 In addition, potential complications including lymphocyst formation, laceration of vessels, transected ureters, and wound infection may occur. Due to the inadequate evidence on the therapeutic significance of this approach in improving survival and associated morbidity, routine use of lymphadenectomy requires further investigations.
Another approach was escalation of the dose of radiotherapy, based on the correlation of pelvic disease control with radiation dose to point A. 12 However, the maximum dose that can be delivered was limited by normal tissue tolerance, especially that of small bowel, rectum, and urinary bladder. With recent advances in technology including intensity-modulated radiation therapy, CT-or MRI-based brachytherapy planning, a higher radiation dose can be delivered to the target volume without concurrent increase in toxicities. [23] [24] [25] Whether the escalation in radiation dose translates into therapeutic gain in treating cervical cancers needs to be explored further in studies with longer follow-up. Ways to reduce uncertainties about inter-and intra-fractional motion and tumour regression during treatment also need to be addressed.
The second potential way to reduce distant metastasis is by eradicating disseminated tumour cells outside radiation field by systemic chemotherapy. Cisplatinbased chemoirradiation was the recommended standard of care by the US National Cancer Institute since 1999, based on results from five randomised trials. [26] [27] [28] [29] [30] A subsequent meta-analysis confirmed improvement in progression-free survival, overall survival, and local and distant disease control with this treatment strategy. 4 Despite such improvement, survival of patients with locally advanced cervical cancer and those with lymph node involvement remained poor due to high distant failure. Studies aiming to define the optimal agents, dose, combination, and timing of chemotherapy are underway. Neoadjuvant chemotherapy has the potential advantage of shrinking the tumour and controlling microscopic metastasis before definitive treatment. A meta-analysis by the Medical Research Council, UK, including 2074 patients after a median follow-up of 5.7 years showed that neoadjuvant chemotherapy followed by surgery significantly reduced the risk of death (HR = 0.65; p = 0.0004) compared with radiotherapy alone. For neoadjuvant chemotherapy followed by radiotherapy compared with radiotherapy alone, only neoadjuvant chemotherapy with cycle length of ≤14 days (HR = 0.83; p = 0.046), or cisplatin dose intensities of ≥25 mg/m 2 /week (HR = 0.91; p = 0.2) tended to show a survival advantage. 31 However, the authors pointed out that further randomised trials are required to confirm the findings due to heterogeneity of trials, confounding factors, and small quantities of data. Use of adjuvant chemotherapy has been even less well-studied. A phase III randomised trial on adjuvant oral 5-fluorouracil 32 and a retrospective study on adjuvant 5-fluorouracil and cisplatin 33 failed to show a benefit in survival. Without further concrete evidence, use of chemotherapy other than cisplatin concurrent with radiotherapy should only be undertaken in clinical trial settings.
There are several limitations in our study. Firstly, there are the inherent disadvantages of a retrospective study including missing information, selection bias, reporting bias, and unknown confounding variables. Secondly, the imbalance between and the small number of patients in the two arms may render comparison of treatment outcomes less reliable. Thirdly, lack of routine imaging to evaluate lymph node status before and after definitive treatment may cause inaccurate interpretation of treatment efficacy. Lastly, the high proportion of cases with squamous cell carcinoma in this study may account for a slightly lower rate of distant failure in both groups compared with rates reported in the literature.
CONCLUSION
Radical radiotherapy or chemoirradiation is associated with high pelvic control rate (89%-95%) in patients with lymph node involvement. Extended-field radiotherapy with chemotherapy in patients with para-aortic lymph node metastases was well-tolerated and long-term survival may be achieved, albeit these results were based on a small sample size. Due to rarity of this group of patients, analysis involving multiple centres should be considered. Distant recurrence was the main reason of treatment failure, especially for those with advancedstage disease (FIGO III-IVa) or nodal metastases. More effective treatment targeted at early systemic eradication of distant microscopic disease and careful scheduling of systemic treatment into the radiotherapy course is important in improving survival without compromising the highly effective pelvic control.
